Clinical Trial

Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder

NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel…

9 months ago

Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

– Initiated pivotal spiriTED Phase 2b trial in Thyroid Eye Disease (TED) in 2023 and expanded TED clinical development plan,…

9 months ago

Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID

TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a…

9 months ago

Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer

Conduit also appoints prominent intellectual property attorney Jeffrey Lindeman as a Consultant Leadership additions underscore Conduit’s commitment to strengthening and…

9 months ago

SPEVIGO® approved for expanded indications in China and the US

Generalized pustular psoriasis (GPP) is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin and systemic symptoms, such as…

9 months ago

Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024

MELBOURNE, Australia and PRINCETON, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company…

9 months ago

XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial

CALGARY, Alberta, March 19, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX…

9 months ago

USA Patient Registry Software Market Outlook to 2028, Featuring IQVIA, Optum (UnitedHealth Group), Phytel, Dacima Software, FIGmd, Syapse and Pharos Innovations – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "USA Patient Registry Software Market Outlook to 2028" report has been added to ResearchAndMarkets.com's offering. The United States…

9 months ago

Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme

PharmAla now first company to supply both MDMA and Psilocybin into the Australian MarketVANCOUVER, British Columbia, March 18, 2024 (GLOBE…

9 months ago

Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea

Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024SCOTTSDALE, Ariz., March 18, 2024 (GLOBE NEWSWIRE) -- Journey…

9 months ago